Vinva Investment Management Ltd Grows Holdings in Edwards Lifesciences Co. (NYSE:EW)

Vinva Investment Management Ltd raised its position in shares of Edwards Lifesciences Co. (NYSE:EWFree Report) by 18.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,945 shares of the medical research company’s stock after purchasing an additional 3,641 shares during the quarter. Vinva Investment Management Ltd’s holdings in Edwards Lifesciences were worth $1,760,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Norges Bank bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $648,540,000. Brown Advisory Inc. lifted its stake in Edwards Lifesciences by 20.1% in the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after purchasing an additional 3,048,274 shares in the last quarter. CIBC Private Wealth Group LLC lifted its stake in Edwards Lifesciences by 197.0% in the 4th quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock worth $262,815,000 after purchasing an additional 2,286,119 shares in the last quarter. AustralianSuper Pty Ltd bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $168,519,000. Finally, Sands Capital Management LLC grew its position in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock valued at $465,407,000 after purchasing an additional 1,567,526 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Barclays increased their price target on Edwards Lifesciences from $100.00 to $101.00 and gave the company an “overweight” rating in a research note on Tuesday, May 7th. Evercore ISI lowered their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday, April 26th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Finally, OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.06.

Read Our Latest Research Report on Edwards Lifesciences

Edwards Lifesciences Stock Up 0.5 %

NYSE EW traded up $0.42 during midday trading on Friday, hitting $88.10. 1,681,549 shares of the company traded hands, compared to its average volume of 3,453,054. The company has a market cap of $53.09 billion, a PE ratio of 37.76, a price-to-earnings-growth ratio of 3.19 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The company’s 50-day simple moving average is $88.50 and its 200-day simple moving average is $82.87.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the stock in a transaction dated Monday, May 6th. The stock was purchased at an average price of $85.74 per share, with a total value of $49,729.20. Following the transaction, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at $1,809,931.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bernard J. Zovighian purchased 580 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders have sold a total of 151,004 shares of company stock valued at $13,469,601 in the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.